Hey GP2C and Rett University Community!
More encouraging news from the Taysha Gene Therapy trials… your research dollars and donations are making a difference!
Taysha Reports Preliminary Results on Gene Therapy Trial Patient #1
…TSHA-102 was well-tolerated with no treatment-emergent serious adverse events (SAEs) as of six-week assessment and improvement in key efficacy measures, including Clinical Global Impression – Improvement (CGI-I), Clinical Global Impression – Severity (CGI-S) and Rett Syndrome Behavior Questionnaire (RSBQ), four weeks post-treatment.
…observed clinical improvement in multiple domains, including autonomic function (sleep and breathing), vocalization, as well as gross motor skills (gained ability to sit unassisted for three minutes) and fine motor skills (gained ability to hold objects), supported by initial clinical data and video evidence.
…U.S. Food and Drug Administration (FDA) cleared the Investigational New Drug (IND) application for TSHA-102 in pediatric patients with Rett Syndrome.
“We are pleased with the progress we have made this quarter in the clinical evaluation of our two lead investigational programs. For TSHA-102 in Rett syndrome, we believe the initial safety profile and significant clinical improvements seen in the first adult patient with severe disease four weeks post-treatment reinforces the transformative potential of our gene therapy to address the root cause of Rett syndrome…”
READ MORE ABOUT THE FULL PRELIMINARY ASSESSMENTS AND PROGRESS AT THE LINKS BELOW!!!
https://reverserett.org/site/assets/files/8558/taysha_rett_community_letter_august_14_2023.pdf
